Acknowledgements
This shared data set was provided by the Breast Imaging Research Program at UCSF, in collaboration with ACRIN (American College of Radiology Imaging Network), the I-SPY TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and molecular Analysis), and TCIA.
Funding sources include:
UCSF | R01 CA132870 and U01 CA151235 |
ACRIN | CA079778 and CA080098 |
I-SPY | CA31964 and CA33601 |
David Newitt, PhD, UCSF
Nola Hylton, PhD, UCSF
Summary
BACKGROUND
ACRIN 6657 was designed as a prospective study to test MRI for ability to predict response to treatment and risk-of-recurrence in patients with stage 2 or 3 breast cancer receiving neoadjuvant chemotherapy (NACT). ACRIN 6657 was conducted as a companion study to CALGB 150007, a correlative science study evaluating tissue-based biomarkers in the setting of neoadjuvant treatment of breast cancer. Collectively, CALGB 150007 and ACRIN 6657 formed the basis of the multicenter Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis (I-SPY TRIAL) breast cancer trial, a study of imaging and tissue-based biomarkers for predicting response and survivalAdd protocol references for all three studies.
Participant Eligibility and Enrollment: Criteria for inclusion were patients enrolling on CALGB 150007 with T3 tumors measuring at least 3 cm in diameter by clinical exam or imaging and receiving neoadjuvant chemotherapy with an anthracycline-cyclophosphamide regimen alone or followed by a taxane. Pregnant patients and those with ferromagnetic prostheses were excluded from the study. The study was open to enrollment from May 2002 to March 2006. 237 patients were enrolled, of which 230 met eligibility criteria.
Requirements for MR imaging (As specified in the ACRIN 6657 protocol )
Imaging time points: MRI exams were performed within four weeks prior to starting anthracycline-cyclophosphamide chemotherapy (T1, MRI1), at least 2 weeks after the first cycle of AC and prior to the second cycle of AC (T2, MRI2), between anthracycline-cyclophosphamide treatment and taxane therapy if taxane was administered (T3, MRI3), and after the final chemotherapy treatment and prior to surgery (T4, MRI4). The study schema is shown in Figure 1
Figure 1. I-SPY 1 TRIAL and ACRIN 6657 study schema.
Imaging protocol: MR imaging was performed on a 1.5 Tesla field strength scanner using a dedicated breast radiofrequency coil. The image acquisition protocol included a localization scan and T2-weighted sequence followed by a contrast-enhanced T1-weighted series. All imaging was performed unilaterally over the symptomatic breast and in the sagittal orientation. The contrast-enhanced series consisted of a high resolution (≤1mm in-plane spatial resolution) three-dimensional, fat-suppressed, T1-weighted gradient echo sequence with TR≤20 ms, TE = 4.5 ms, flip angle ≤ 45º, 16-18 cm field-of-view, minimum matrix 256x192, 64 slices, slice thickness ≤ 2.5 mm. Scan time length for the T1-weighted sequence was required to be between 4.5 and 5 minutes. The sequence was acquired once before contrast injection and repeated at least twice following injection.
Tumor diameter measurement and volumetric analysis: Tumor longest diameter (LD) was measured by the site radiologist as the greatest extent of disease on baseline MR images, including intervening areas of non-enhancing tissue. The same measurement direction was used on all subsequent MRI exams. The primary predictor variable, functional tumor volume (FTV) was measured from contrast-enhanced images using the signal enhancement ratio (SER) method. Voluetric analysis, including Quality Control assessment, was performed centrally at the breast MR imaging laboratory at University of California at San Francisco (UCSF).
Further information can be found at:
- ACRIN 6657 Protocol http://www.acrin.org/6657_protocol.aspx
- I-SPY TRIAL http://ncicb.nci.nih.gov/tools/translation_research/isp
- CALGB 150007 http://www.cancer.gov/clinicaltrials/search/view?cdrid=69280&version=HealthProfessional
- Data Dictionary
Abbreviations
ACRIN American College of Radiology Imaging Network
I-SPY TRIAL Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis
CALGB Cancer and Leukemia Group B
NACT Neoadjuvant chemotherapy
FTV Functional Tumor Volume
Data Access
Imaging Data
This is a limited access data set. To request access, please contact (ACRIN Contact). If access is granted you will be able to view and download these images on The Cancer Imaging Archive (TCIA) by logging in and selecting the I-SPY1 collection. This data set will be made publicly available on or before XXXX XX, 20XX.
Collection Statistics | (updated 6/18/2015) |
---|---|
Modalities | MR |
Number of Patients | 222 |
Number of Studies | 847 |
Number of Series | 7880 |
Number of Images | 386,528 |
Images Size (GB) | 76.2 GigaBytes |
((( Insert full acknowledgement lists here )))
((( END OF PUBLIC PAGE - REST GOES ON SEPARATE PAGE ACCESSIBLE TO THOSE WITH STUDY DOWNLOAD PRIVILEDGES )))
ISPY 1 - Collection Description
If you are unsure how to download this Collection please view our quick guide on Searching by Collection or refer to our The Cancer Imaging Archive User's Guide for more detailed instructions on using the site.
Imaging Data Transfer Process
The processing of the MR image data for ACRIN 6657 / I-SPY 1 consisted of the following steps between image acquisition and the creation of this shared data set on TCIA:
- MRI studies were sent from the study centers to ACRIN Core Lab either via media (DVD) or the TRIAD program
- Image data were de-identified and centrally archived at ACRIN Core Lab
- Archived data was sent to the breast MR imaging laboratory at University of California at San Francisco (UCSF) for volumetric analysis.
- De-identified image data, derived analysis maps and segmentations, and ancillary data files were transferred from UCSF to TCIA for data sharing.
While every effort was made to preserve the integrity of both the original image data and image meta-data (DICOM attributes, public and private), strict adherence to HIPPA guidelines for patient confidentiality may have resulted in loss of some data. If any questions arise, or any patient PHI is found in any data on this collection, please contact David Newitt at the Breast Imaging Research Program, UCSF (david.newitt@ucsf.edu).
Curated Data Sets
Summary
In addition to the complete set of ACRIN 6657 imaging studies, curated data sets based on UCSF QC assessment and data completeness are provided in the form of TCIA shared lists for selective downloads.
Shared Lists: See descriptions below under "Curated Data Sets"
- Longest Diameter (LD) dataset -
- Good SER Functional Tumor Volume (FTV) dataset
- ACRIN 6657 Primary Aim Analysis dataset
Level 0: All I-SPY 1 Dataset
847 MR on-study studies (222 subjects) in UCSF image database.
One patient in the image data collection (I-SPY ID 1079 ) does not appear in the Feb. 2, 2011 I-SPY FINAL LOCKED clinical data set. So no clinical data is available.
Level 1: LD Dataset
Studies with MRI measured longest diameter
839 MR studies have LD reported in the I-SPY 1 clinical database
834 MR studies (219 subjects) in UCSF image database with LD
5 studies that have LD measurement are missing from | ||
---|---|---|
1071, T1 | 1101, T3 | 1187, T4 |
Level 2a: Good SER Volume Dataset – updated 9/3/14
Level 2a consists of 708 MR studies (208 subjects) in the UCSF image database which, following quality review in 2014, were judged to have sufficiently good image quality and protocol compliance for volumetric DCE SER analysis. Rejection criteria included: incomplete volumetric DCE acquisitions, lack of a 2nd post-contrast acquisition, variability in fat suppression across the image, observed patient motion during the DCE acquisition
7 studies in Level 2a that do NOT have LD measures: | ||
---|---|---|
ID 1059, T4 | ID 1192, T2 | ID 1215, T1 |
- Patient 1079 does not appear in the Feb. 2, 2011 I-SPY FINAL LOCKED clinical data set. So no clinical data is available.
Level 2b: SER Volume Dataset submitted to ACRIN in 2008
This data set is not provided as a shared list, as it is not recommended for use in any analysis. It is described here because it is the data set from which the Level 3 (primary aim analysis) set was derived.
Level 2b consists of 707 MR studies (207 subjects) in the UCSF image database which were submitted to ACRIN at the close of the trial in 2008. Inclusion and exclusion was determined by quality and protocol reviews available at that time. In addition to the exclusion criteria listed for Level 2a, studies done with imaging in the axial plane, in violation of the sagittal orientation specified in the trial imaging protocol, were excluded due to processing limitations of the analysis software. Similarly, bi-lateral sagittal acquisitions (alternating left and right volumetric acquisitions) were excluded.
Specific inclusion/exclusion differences between Levels 2a and 2b:
15 studies accepted for SER analysis since 2008 (in Level 2a but not in 2b) | ||
---|---|---|
ID 1005, T3 | ID 1110, T4 | ID 1203, T4 |
14 studies rejected since 2008 (in Level 2b but not in 2a) | ||
---|---|---|
ID 1035, T4 * | ID 1055, T1 * | ID 1206, T1 |
* Subjects that were included in the primary aim analysis (Level 3) |
Level 3: Subset of Level 2b used in primary aim analysis
586 MR studies (162 subjects) in UCSF image database
45 subjects excluded from Level 2b set | |||||
---|---|---|---|---|---|
ID 1027 ID 1040 ID 1045 ID 1046 ID 1048 ID 1054 ID 1063 ID 1067 | ID 1079 ID 1084 ID 1103 ID 1110 ID 1120 ID 1137 ID 1139 ID 1152 | ID 1157 ID 1159 ID 1160 ID 1167 ID 1171 ID 1176 ID 1177 ID 1180 | ID 1182 ID 1185 ID 1187 ID 1189 ID 1192 ID 1194 ID 1203 ID 1206 | ID 1210 ID 1212 ID 1214 ID 1215 ID 1219 ID 1221 ID 1222 ID 1228 | ID 1234 ID 1235 ID 1237 ID 1238
ineligible: Case #: 128 |
Data Dictionary
A data dictionary is provided. The dictionary includes descriptions of all private DICOM attributes used in the derived maps and segmentations generated by the volumetric analysis and QC evaluations. Also included are descriptions of ancillary data provided, including demographic, clinical and survival data.